Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Gets Early Win In Challenge To Merck's Zetia Patent Claims

This article was originally published in PharmAsia News

Executive Summary

India's Glenmark Phrmaceuticals has won a favorable decision in a U.S. court against Merck and its patents on Zetia (ezetimibe) for controlling cholesterol

You may also be interested in...



Risk, Reward Sharing Extends To Generics: Glenmark, Par Tango As Lanuch Prospects For Zetia Copies Brighten

MUMBAI - Its raining deals for the Indian drug maker Glenmark. A day after the $450 million generics-cum-innovation driven pharma signed an out-licensing agreement with Sanofi Aventis for a novel research compound in pain management, it has now announced another one-of-its-kind licensing agreement - this time with Par Pharma to market generic versions of Merck/Schering Plough's $1.4 billion cholesterol drug Zetia (ezetimibe) in the United States

Teligent Calls In The Cavalry As Warning Letter Threatens To Overwhelm

Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.

Pfizer Partners With Premier To Supply Critical Injectables

Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel